title: The effects of oral RNA and intraperitoneal nucleoside-nucleotide administration on methicillin-resistant Staphylococcus aureus infection in mice.
abstract: The effects of oral RNA and intraperitoneal nucleoside-nucleotide mixture administration on methicillin-resistant Staphylococcus aureus (MRSA) strain 8985N infection were studied in mice. BALB/c mice were fed a nucleic acid-free diet or nucleic acid-free diet supplemented with 0.5% or 2.5% ribonucleic acid (RNA) for 30 days. Nucleoside-nucleotide mixture or saline (control) was intraperitoneally administered daily to these rats except for the 2.5% RNA group, which received saline only. On the 10th day of this treatment, the mice were inoculated intravenously with the viable MRSA organisms. Susceptibility to the MRSA was determined by animal survival and recovery of the MRSA from the organs. The survival rates in the three groups that were administered saline were 29%, 35%, and 40% for nucleic acid-free diet, 0.5% RNA, and 2.5% RNA groups, respectively, whereas in the two groups that received the nucleoside-nucleotide mixture the rates were 69% for the nucleic acid-free diet group and 55% for 0.5% RNA group. The susceptibility of the mice to the MRSA challenge was not affected by dietary RNA, which indicates the ineffectiveness of oral RNA. The combined survival rate in the two nucleoside-nucleotide groups (64%) was statistically different (p < .01) from that in the three saline groups (34%). There was a greater reduction in viable organism recovery in the kidney and spleen of the surviving mice that had been administered the nucleoside-nucleotide mixture than in those administered saline.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Nutrition, University of the Ryukyus, Okinawa, Japan.
authors.forename: A A
authors.initials: AA
authors.lastname: Adjei
authors.forename: F
authors.initials: F
authors.lastname: Takamine
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: K
authors.initials: K
authors.lastname: Shiokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: L
authors.initials: L
authors.lastname: Asato
authors.forename: S
authors.initials: S
authors.lastname: Shinjo
authors.forename: T
authors.initials: T
authors.lastname: Imamura
authors.forename: S
authors.initials: S
authors.lastname: Yamamoto
mesh_terms: D000284:Administration, Oral; D000818:Animals; D005260:Female; D007274:Injections, Intraperitoneal; D016106:Methicillin Resistance / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009705:Nucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D009711:Nucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D012313:RNA / Q000008:administration & dosage / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000276:immunology / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects
chemical_list: D009705:Nucleosides; D009711:Nucleotides; D012313:RNA